|1.||Barry, Clifton E: 7 articles (01/2014 - 01/2006)|
|2.||Manjunatha, Ujjini H: 5 articles (01/2014 - 01/2006)|
|3.||Dowd, Cynthia S: 5 articles (01/2012 - 01/2006)|
|4.||Tyagi, Sandeep: 5 articles (01/2011 - 06/2005)|
|5.||Dawson, Rodney: 4 articles (05/2015 - 08/2010)|
|6.||Tasneen, Rokeya: 4 articles (01/2015 - 04/2008)|
|7.||Peloquin, Charles A: 4 articles (12/2011 - 08/2006)|
|8.||Diacon, Andreas H: 3 articles (05/2015 - 08/2010)|
|9.||van Niekerk, Christo: 3 articles (05/2015 - 08/2010)|
|10.||Venter, Amour: 3 articles (05/2015 - 08/2010)|
04/01/2009 - "We formulated PA-824, a nitroimidazopyran with promise for the treatment of tuberculosis, for efficient aerosol delivery to the lungs in a dry powder porous particle form. "
09/01/2009 - "The results of these studies, combined with the demonstrated activity of PA-824 against drug-sensitive and multidrug-resistant Mycobacterium tuberculosis, support the investigation of this novel compound for the treatment of tuberculosis."
08/01/2006 - "In this study, we used the murine model of experimental tuberculosis therapy to determine whether incorporation of the investigational new nitroimidazopyran PA-824 into the standard first-line regimen has the potential to shorten the 6-month duration of treatment. "
01/10/2006 - "PA-824 is a promising new compound for the treatment of tuberculosis that is currently undergoing human trials. "
09/01/2015 - "tuberculosis mutants, 83% harbored a single mutation in one of five nonessential genes associated with either PA-824 prodrug activation (ddn, 29%; fgd1, 7%) or the tangential F420 biosynthetic pathway (fbiA, 19%; fbiB, 2%; fbiC, 26%). "
01/01/2011 - "Beginning 2 weeks after aerosol infection with Mycobacterium tuberculosis, total PA-824 doses from 144 to 4,608 mg/kg were administered as 3, 4, 8, 12, 24, or 48 divided doses over 24 days. "
04/01/2010 - "Four weeks after infection by the pulmonary route, animals received daily treatment for 4 weeks of either a high or a low dose of PA-824 dry powder aerosol. "
01/01/2015 - "Low-dose aerosol infection models of acute and chronic murine tuberculosis reveal time- and dose-dependent in vivo bactericidal activity that is at least as potent as that of delamanid and more potent than that of PA-824. "
04/01/2010 - "The objective of the present study was to evaluate the effects of these PA-824 therapeutic aerosols on the extent of TB infection in the low-inoculum aerosol infection guinea pig model. "
12/01/2014 - "tuberculosis infection, separate groups of mice were left untreated (negative controls) or were treated with either rifampicin, isoniazid (INH) or PA-824. "
12/01/2014 - "The bicyclic nitroimidazole-like molecule PA-824 has activity both against replicating and hypoxic non-replicating Mycobacterium tuberculosis, raising the possibility that it may have a role in the treatment of latent tuberculosis infection (LTBI). "
12/01/2014 - "PA-824 is as effective as isoniazid against latent tuberculosis infection in C3HeB/FeJ mice."
01/01/2013 - "In this context, PA-824 was analyzed for its activity against latent tuberculosis under anaerobic conditions and compared with rifampicin (RIF) and pyrazinamide (PZA). "
03/01/2011 - "On the other hand, co-administration of moxifloxacin and PA-824 could be active against latent tuberculosis, whereas linezolid, PA-824 and TMC207 are candidates for a rifampin-free regimen in multidrug-resistant and extensively-resistant tuberculosis. "
|4.||Body Weight (Weight, Body)
06/01/2012 - "Fifteen patients per cohort received oral PA-824 in doses of 50 mg, 100 mg, 150 mg, or 200 mg per kg body weight per day for 14 days. "
04/01/2009 - "Pharmacokinetic parameters were determined in guinea pigs after the pulmonary administration of the PA-824 powder formulation at three doses (20, 40, and 60 mg/kg of body weight) and compared to those after the intravenous (20 mg/kg) and oral (40 mg/kg) delivery of the drug. "
06/01/2005 - "In a short-course mouse infection model, the efficacy of PA-824 at 50, 100, and 300 mg/kg of body weight formulated in methylcellulose or cyclodextrin/lecithin after nine oral treatments was compared with those of isoniazid, rifampin, and moxifloxacin. "
|5.||Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis)
04/01/2015 - "After decades of quiescence in the development of antituberculosis medications, bedaquiline and delamanid have been conditionally approved for the treatment of drug-resistant tuberculosis, while several other novel compounds (AZD5847, PA-824, SQ109 and sutezolid) have been evaluated in phase II clinical trials. "
01/01/2015 - "The nitroimidazo-oxazole delamanid (OPC-67683, Deltyba) is in phase III trials for the treatment of multidrug-resistant tuberculosis, while the nitroimidazo-oxazine PA-824 is entering phase III for drug-sensitive and drug-resistant tuberculosis. "
08/01/2006 - "Future preclinical studies should include the evaluation of novel combinations of PA-824 with new drug candidates in addition to existing antituberculosis drugs for their potential to substantially improve the treatment of both drug-susceptible and multidrug-resistant tuberculosis."
06/01/2012 - "A dose of 100 mg to 200 mg PA-824 daily appears to be safe and efficacious and will be further evaluated as a component of novel antituberculosis regimens for drug-sensitive and drug-resistant tuberculosis."
06/01/2005 - "Together, these data strongly support further evaluation of PA-824 in combination with first- or second-line antituberculosis drugs to determine its potential contribution to the treatment of drug-susceptible or multidrug-resistant tuberculosis, respectively."
|2.||Combination Drug Therapy (Combination Chemotherapy)